<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04809584</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-58503</org_study_id>
    <secondary_id>PROS0103</secondary_id>
    <secondary_id>IRB-58503</secondary_id>
    <nct_id>NCT04809584</nct_id>
  </id_info>
  <brief_title>18F-DCFPyL PET/MRI in Regional Nodal&amp;Distant Metastases Detection in Intermediate &amp;HR Prostate Cancer</brief_title>
  <official_title>18F-DCFPyL PET/MRI for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      The purpose of this research study is to see if patients' tumor can be identified by&#xD;
      18F-DCFPyL PET/MRI scan. The radioactive study agent, 18FDCFPyL, combined with PET/MRI scan&#xD;
      may be able to identify smaller tumors than the standard of care contrast-enhanced CT or MRI&#xD;
      scan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an expanded access study with a total of 100 participants with newly diagnosed&#xD;
      intermediate or high-risk prostate cancer scheduled to undergo prostatectomy and lymph node&#xD;
      dissection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F18-DCFPyL</intervention_name>
    <description>Participant will be injected iv with 9 mCi ± 20% of 18F-DCFPyL</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadolinium</intervention_name>
    <description>Contrast agent</description>
    <other_name>motexafin gadolinium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan</intervention_name>
    <description>Imaging test that combines PET (positron emission tomography) and MRI (magnetic resonance imaging)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is older than 18-year-old&#xD;
&#xD;
          2. Biopsy proven prostate adenocarcinoma&#xD;
&#xD;
          3. Planned prostatectomy with lymph node dissection&#xD;
&#xD;
          4. Intermediate to high-risk disease (as determined by elevated Prostate-specific antigen&#xD;
             (PSA) [PSA&gt;10], T-stage [T2b or greater], Gleason score [Gleason score &gt; 6] or other&#xD;
             risk factors)&#xD;
&#xD;
          5. Able to provide written consent&#xD;
&#xD;
          6. Karnofsky performance status of ³50 (or Eastern Cooperative Oncology Group (ECOG)&#xD;
             /World Health Organization (WHO) equivalent)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Neoadjuvant chemotherapy or radiation therapy prior to prostatectomy including focal&#xD;
             ablation techniques (HiFu)&#xD;
&#xD;
          2. Androgen deprivation therapy or other neoadjuvant treatments prior to PET imaging&#xD;
             surgery&#xD;
&#xD;
          3. Metallic implants (contraindicated for MRI)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Men &gt;/= 18 years of age will be recruited.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Andrei H Iagaru</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Universiy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pranav Hegde</last_name>
    <phone>650-721-4080</phone>
    <email>Pranavhegde@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Pranav Hedge</last_name>
      <phone>650-721-4080</phone>
      <email>Pranavhegde@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Andrei H Iagaru, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motexafin gadolinium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

